Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
D06BB01,J05AB02,S01AD01
CAS registry number (Chemical Abstracts Service)
0000054-42-2
Chemical Formula
C9-H11-I-N2-O5
Molecular Weight
354
Therapeutic Category
Antiviral agent
Chemical Name
Uridine, 2'-deoxy-5-iodo-
Foreign Names
- Idoxuridinum (Latin)
- Idoxuridin (German)
- Idoxuridine (French)
- Idoxuridina (Spanish)
Generic Names
- Idoxuridina (OS: DCIT)
- Idoxuridine (OS: BAN, DCF, JAN, USAN)
- 5 IUDR (IS)
- Allergan 201 (IS: Allergan)
- I.D.U.R. (IS)
- IDU (IS)
- SKF 14287 (IS)
- Idoxuridin (PH: Ph. Eur. 6)
- Idoxuridine (PH: BP 2010, Ph. Eur. 6, Ph. Int. 4, USP 32, JP XIV)
- Idoxuridinum (PH: Ph. Int. 4, Ph. Eur. 6)
Brand Names
- Dendrid
Alcon, Botswana; Alcon, Eritrea; Alcon, Ghana; Alcon, Kenya; Alcon, Malawi; Alcon, Namibia; Alcon, Nigeria; Alcon, Tanzania; Alcon, Uganda; Alcon, United States; Alcon, Zambia; Alcon, Zimbabwe - Herpesine
Nikkho, Brazil - Herpid
Astellas, United Kingdom - Herpidu
Ciba Vision, Bangladesh - Herplex
Allergan, United States; Belupo, Bosnia & Herzegowina; Opso Saline, Bangladesh - IDU
Kaken Seiyaku, Japan; Senju Seiyaku, Japan - Iducher
Farmigea, Italy - Idulea
Elea, Argentina - Idustatin
Sanofi-Aventis, Italy - Isotic Ixodine
Fahrenheit, Indonesia - Keresid
GlaxoSmithKline, Ethiopia - Oftan IDU
Santen, Georgia; Santen, Russian Federation - Ridinox
Bell, India - Virexen
Viñas, Spain; Will, Luxembourg - Virpex
AHP, Luxembourg - Virunguent
Hermal, Luxembourg - Virunguent (Idoxuridine and Dimethyl Sulfoxide)
Almirall Hermal, Germany
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Click for further information on drug naming conventions and International Nonproprietary Names.
No comments:
Post a Comment